Stimuli-responsive systems for controlled drug delivery
First Claim
Patent Images
1. A material for delivery of a therapeutic agent in response to an indicator, comprising:
- conjugates that include a therapeutic agent covalently linked to a polymer, wherein the polymer includes two or more indicator analogs; and
polyfunctional cross-linking agents that cross-link conjugates by non-covalently interacting with indicator analogs on different conjugates, wherein;
the material is insoluble in the absence of an indicator that competes with the indicator analogs for non-covalent interactions with the cross-linking agents;
conjugates are released from the material in the presence of the indicator at a rate that varies within physiological concentrations of the indicator;
the indicator is glucose;
the indicator analogs comprise glucose and/or mannose residues; and
the therapeutic agent is insulin or an insulin secretogue.
2 Assignments
0 Petitions
Accused Products
Abstract
A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.
52 Citations
49 Claims
-
1. A material for delivery of a therapeutic agent in response to an indicator, comprising:
-
conjugates that include a therapeutic agent covalently linked to a polymer, wherein the polymer includes two or more indicator analogs; and polyfunctional cross-linking agents that cross-link conjugates by non-covalently interacting with indicator analogs on different conjugates, wherein; the material is insoluble in the absence of an indicator that competes with the indicator analogs for non-covalent interactions with the cross-linking agents; conjugates are released from the material in the presence of the indicator at a rate that varies within physiological concentrations of the indicator; the indicator is glucose; the indicator analogs comprise glucose and/or mannose residues; and the therapeutic agent is insulin or an insulin secretogue. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)
-
Specification